<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34368369</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2314-6753</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2021</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Journal of diabetes research</Title>
          <ISOAbbreviation>J Diabetes Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metformin Increases Protein Phosphatase 2A Activity in Primary Human Skeletal Muscle Cells Derived from Lean Healthy Participants.</ArticleTitle>
        <Pagination>
          <StartPage>9979234</StartPage>
          <MedlinePgn>9979234</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">9979234</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/9979234</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate if PP2A plays a role in metformin-induced insulin sensitivity improvement in human skeletal muscle cells. <i>Participants</i>. Eight lean insulin-sensitive nondiabetic participants (4 females and 4 males; age: 21.0 ± 1.0 years; BMI: 22.0 ± 0.7 kg/m<sup>2</sup>; 2-hour OGTT: 97.0 ± 6.0 mg/dl; HbA1c: 5.3 ± 0.1%; fasting plasma glucose: 87.0 ± 2.0 mg/dl; <i>M</i> value; 11.0 ± 1.0 mg/kgBW/min).</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">A hyperinsulinemic-euglycemic clamp was performed to assess insulin sensitivity in human subjects, and skeletal muscle biopsy samples were obtained. Primary human skeletal muscle cells (shown to retain metabolic characteristics of donors) were cultured from these muscle biopsies that included 8 lean insulin-sensitive participants. Cultured cells were expanded, differentiated into myotubes, and treated with 50 <i>μ</i>M metformin for 24 hours before harvesting. PP2Ac activity was measured by a phosphatase activity assay kit (Millipore) according to the manufacturer's protocol.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The results indicated that metformin significantly increased the activity of PP2A in the myotubes for all 8 lean insulin-sensitive nondiabetic participants, and the average fold increase is 1.54 ± 0.11 (<i>P</i> &lt; 0.001).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results provided the first evidence that metformin can activate PP2A in human skeletal muscle cells derived from lean healthy insulin-sensitive participants and may help to understand metformin's action in skeletal muscle in humans.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Aktham Mestareehi et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mestareehi</LastName>
            <ForeName>Aktham</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-1478-6310</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xiangmin</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0001-9285-1619</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seyoum</LastName>
            <ForeName>Berhane</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Wayne State University School of Medicine, Wayne State University, Detroit, MI 48201, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Msallaty</LastName>
            <ForeName>Zaher</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Wayne State University School of Medicine, Wayne State University, Detroit, MI 48201, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mallisho</LastName>
            <ForeName>Abdullah</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-9181-1540</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Wayne State University School of Medicine, Wayne State University, Detroit, MI 48201, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burghardt</LastName>
            <ForeName>Kyle Jon</ForeName>
            <Initials>KJ</Initials>
            <Identifier Source="ORCID">0000-0003-2319-5149</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy/Health Sciences, Wayne State University, Detroit, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kowluru</LastName>
            <ForeName>Anjaneyulu</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-1700-0077</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Program for Translational Research in Diabetes, Biomedical Research Service, John D. Dingell VA Medical Center, Detroit, MI 48201, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>Zhengping</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-2975-7205</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>T32 HL120822</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 EY014370</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 EY022230</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>IK6 BX005383</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>I01 BX004663</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK107666</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK081750</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Diabetes Res</MedlineTA>
        <NlmUniqueID>101605237</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>9100L32L2N</RegistryNumber>
          <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.16</RegistryNumber>
          <NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007333" MajorTopicYN="N">Insulin Resistance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032342" MajorTopicYN="N">Muscle Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054648" MajorTopicYN="N">Protein Phosphatase 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013851" MajorTopicYN="N">Thinness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no conflict of interest and have nothing to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34368369</ArticleId>
        <ArticleId IdType="pmc">PMC8342103</ArticleId>
        <ArticleId IdType="doi">10.1155/2021/9979234</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zierath J. R., Krook A., Wallberg-Henriksson H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia. 2000;43(7):821–835. doi: 10.1007/s001250051457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s001250051457</ArticleId>
            <ArticleId IdType="pubmed">10952453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunter R. W., Hughey C. C., Lantier L., et al.  Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nature Medicine. 2018;24(9):1395–1406. doi: 10.1038/s41591-018-0159-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0159-7</ArticleId>
            <ArticleId IdType="pmc">PMC6207338</ArticleId>
            <ArticleId IdType="pubmed">30150719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Musi N., Hirshman M. F., Nygren J., et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51(7):2074–2081. doi: 10.2337/diabetes.51.7.2074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.51.7.2074</ArticleId>
            <ArticleId IdType="pubmed">12086935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shlobin N. A., Sander J. W. Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: a scoping review. Epilepsy &amp; Behavior. 2020;106:p. 107043. doi: 10.1016/j.yebeh.2020.107043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2020.107043</ArticleId>
            <ArticleId IdType="pubmed">32217418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nesci V., Russo E., Arcidiacono B., et al.  Metabolic alterations predispose to seizure development in high-fat diet-treated mice: the role of metformin. Molecular Neurobiology. 2020;57(11):4778–4789. doi: 10.1007/s12035-020-02062-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-020-02062-6</ArticleId>
            <ArticleId IdType="pubmed">32785826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yimer E. M., Surur A., Wondafrash D. Z., Gebre A. K. The effect of metformin in experimentally induced animal models of epileptic seizure. Behavioural Neurology. 2019;2019:13. doi: 10.1155/2019/6234758.6234758</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/6234758</ArticleId>
            <ArticleId IdType="pmc">PMC6378775</ArticleId>
            <ArticleId IdType="pubmed">30863464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brueggeman L., Sturgeon M. L., Martin R. M., et al.  Drug repositioning in epilepsy reveals novel antiseizure candidates. Annals of Clinical Translational Neurology. 2019;6(2):295–309. doi: 10.1002/acn3.703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.703</ArticleId>
            <ArticleId IdType="pmc">PMC6389756</ArticleId>
            <ArticleId IdType="pubmed">30847362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowluru A., Matti A. Hyperactivation of protein phosphatase 2A in models of glucolipotoxicity and diabetes: potential mechanisms and functional consequences. Biochemical Pharmacology. 2012;84(5):591–597. doi: 10.1016/j.bcp.2012.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2012.05.003</ArticleId>
            <ArticleId IdType="pubmed">22583922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Lu L., Zhong X., et al.  Metformin reduced NLRP3 inflammasome activity in Ox-LDL stimulated macrophages through adenosine monophosphate activated protein kinase and protein phosphatase 2A. European Journal of Pharmacology. 2019;852:99–106. doi: 10.1016/j.ejphar.2019.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2019.03.006</ArticleId>
            <ArticleId IdType="pubmed">30851273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kickstein E., Krauss S., Thornhill P., et al.  Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(50):21830–21835. doi: 10.1073/pnas.0912793107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0912793107</ArticleId>
            <ArticleId IdType="pmc">PMC3003072</ArticleId>
            <ArticleId IdType="pubmed">21098287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deepa S. S., Zhou L., Ryu J., et al.  APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Molecular Endocrinology. 2011;25(10):1773–1785. doi: 10.1210/me.2011-0082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/me.2011-0082</ArticleId>
            <ArticleId IdType="pmc">PMC3182423</ArticleId>
            <ArticleId IdType="pubmed">21835890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace A. M., Hardigan A., Geraghty P., et al.  Protein phosphatase 2A regulates innate immune and proteolytic responses to cigarette smoke exposure in the lung. Toxicological sciences : an official journal of the Society of Toxicology. 2012;126(2):589–599. doi: 10.1093/toxsci/kfr351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/toxsci/kfr351</ArticleId>
            <ArticleId IdType="pmc">PMC3307605</ArticleId>
            <ArticleId IdType="pubmed">22223484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng G., Kasiganesan H., Baicu C. F., Wallenborn J. G., Kuppuswamy D., Cooper G. Cytoskeletal role in protection of the failing heart by β-adrenergic blockade. American Journal of Physiology Heart and Circulatory Physiology. 2012;302(3):H675–H687. doi: 10.1152/ajpheart.00867.2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpheart.00867.2011</ArticleId>
            <ArticleId IdType="pmc">PMC3353781</ArticleId>
            <ArticleId IdType="pubmed">22081703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman A., Brew B. J., Guillemin G. J. Lead dysregulates serine/threonine protein phosphatases in human neurons. Neurochemical Research. 2011;36(2):195–204. doi: 10.1007/s11064-010-0300-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-010-0300-6</ArticleId>
            <ArticleId IdType="pmc">PMC3023019</ArticleId>
            <ArticleId IdType="pubmed">21046238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson D. B., Pratley R., Ossowski V. Human primary myoblast cell cultures from non-diabetic insulin resistant subjects retain defects in insulin action. The Journal of Clinical Investigation. 1996;98(10):2346–2350. doi: 10.1172/JCI119046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI119046</ArticleId>
            <ArticleId IdType="pmc">PMC507685</ArticleId>
            <ArticleId IdType="pubmed">8941652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henry R. R., Abrams L., Nikoulina S., Ciaraldi T. P. Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures. Diabetes. 1995;44(8):936–946. doi: 10.2337/diab.44.8.936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diab.44.8.936</ArticleId>
            <ArticleId IdType="pubmed">7622000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourlier V., Saint-Laurent C., Louche K., et al.  Enhanced glucose metabolism is preserved in cultured primary myotubes from obese donors in response to exercise training. The Journal of Clinical Endocrinology and Metabolism. 2013;98(9):3739–3747. doi: 10.1210/jc.2013-1727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-1727</ArticleId>
            <ArticleId IdType="pubmed">23884778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi Y., Zhang X., Seyoum B., et al.  Kinome profiling reveals abnormal activity of kinases in skeletal muscle from adults with obesity and insulin resistance. The Journal of Clinical Endocrinology and Metabolism. 2020;105(3):644–659. doi: 10.1210/clinem/dgz115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/clinem/dgz115</ArticleId>
            <ArticleId IdType="pmc">PMC6991621</ArticleId>
            <ArticleId IdType="pubmed">31652310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeFronzo R. A., Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(suppl_2):S157–S163. doi: 10.2337/dc09-S302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc09-S302</ArticleId>
            <ArticleId IdType="pmc">PMC2811436</ArticleId>
            <ArticleId IdType="pubmed">19875544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caruso M., Ma D., Msallaty Z., et al.  Increased interaction with insulin receptor substrate 1, a novel abnormality in insulin resistance and type 2 diabetes. Diabetes. 2014;63(6):1933–1947. doi: 10.2337/db13-1872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db13-1872</ArticleId>
            <ArticleId IdType="pmc">PMC4030113</ArticleId>
            <ArticleId IdType="pubmed">24584551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shanely R. A., Zwetsloot K. A., Triplett N. T., Meaney M. P., Farris G. E., Nieman D. C. Human skeletal muscle biopsy procedures using the modified Bergstrom technique. Journal of visualized experiments : JoVE. 2014;91, article 51812</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4828068</ArticleId>
            <ArticleId IdType="pubmed">25285722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owen M. R., Doran E., Halestrap A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. The Biochemical Journal. 2000;348(3):607–614. doi: 10.1042/bj3480607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/bj3480607</ArticleId>
            <ArticleId IdType="pmc">PMC1221104</ArticleId>
            <ArticleId IdType="pubmed">10839993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X., Liu S., Lin X., et al.  Metformin inhibit lung cancer cell growth and invasion in vitro as well as tumor formation in vivo partially by activating PP2A. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2019;25:836–846. doi: 10.12659/MSM.912059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/MSM.912059</ArticleId>
            <ArticleId IdType="pmc">PMC6362762</ArticleId>
            <ArticleId IdType="pubmed">30693913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacco F., Silvestri A., Posca D., et al.  Deep proteomics of breast cancer cells reveals that metformin rewires signaling networks away from a pro-growth state. Cell Systems. 2016;2(3):159–171. doi: 10.1016/j.cels.2016.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cels.2016.02.005</ArticleId>
            <ArticleId IdType="pubmed">27135362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auger C., Knuth C. M., Abdullahi A., Samadi O., Parousis A., Jeschke M. G. Metformin prevents the pathological browning of subcutaneous white adipose tissue. Molecular Metabolism. 2019;29:12–23. doi: 10.1016/j.molmet.2019.08.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmet.2019.08.011</ArticleId>
            <ArticleId IdType="pmc">PMC6728757</ArticleId>
            <ArticleId IdType="pubmed">31668383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawashima I., Kirito K. Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56α subunit. The Journal of Clinical Investigation. 2016;44(12):1156–1165.e4. doi: 10.1016/j.exphem.2016.08.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exphem.2016.08.005</ArticleId>
            <ArticleId IdType="pubmed">27576133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Sun M. Metformin rescues Parkin protein expression and mitophagy in high glucose- challenged human renal epithelial cells by inhibiting NF-κB via PP2A activation. Life Sciences. 2020;246:p. 117382. doi: 10.1016/j.lfs.2020.117382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.117382</ArticleId>
            <ArticleId IdType="pubmed">32004509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartley D., Cooper G. M. Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. Journal of Cellular Biochemistry. 2002;85(2):304–314. doi: 10.1002/jcb.10135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.10135</ArticleId>
            <ArticleId IdType="pubmed">11948686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowling R. J., Zakikhani M., Fantus I. G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research. 2007;67(22):10804–10812. doi: 10.1158/0008-5472.CAN-07-2310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2310</ArticleId>
            <ArticleId IdType="pubmed">18006825</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
